Details of the Drug

General Information of Drug (ID: DMAF1NB)

Drug Name
Isocarboxazid
Synonyms
BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 231.25
Logarithm of the Partition Coefficient (xlogp) 1.5
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 54.5 +/- 9.1% []
Elimination
Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 - 4 hours [4]
Metabolism
The drug is metabolized via the acetylation in the liver []
Chemical Identifiers
Formula
C12H13N3O2
IUPAC Name
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
Canonical SMILES
CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2
InChI
InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3759
ChEBI ID
CHEBI:93635
CAS Number
59-63-2
DrugBank ID
DB01247
TTD ID
D0I2VK
ACDINA ID
D00331

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monoamine oxidase type A (MAO-A) DTT MAOA 8.14E-01 0.05 0.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Isocarboxazid
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Isocarboxazid and Vilazodone. Depression [6A70-6A7Z] [6]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Isocarboxazid and Vortioxetine. Depression [6A70-6A7Z] [7]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Isocarboxazid and Milnacipran. Depression [6A70-6A7Z] [6]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Isocarboxazid and Desvenlafaxine. Depression [6A70-6A7Z] [6]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Isocarboxazid and Esketamine. Depression [6A70-6A7Z] [8]
Coadministration of a Drug Treating the Disease Different from Isocarboxazid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Isocarboxazid and Methylene blue. Acquired methaemoglobinaemia [3A93] [9]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin-glulisine. Acute diabete complication [5A2Y] [10]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin-aspart. Acute diabete complication [5A2Y] [11]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Isocarboxazid and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [12]
Phenyltoloxamine DMKAEQW Moderate Additive CNS depression effects by the combination of Isocarboxazid and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [12]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Isocarboxazid and Amyl nitrite. Angina pectoris [BA40] [13]
Levalbuterol DM5YBO1 Moderate Additive hypertensive effects by the combination of Isocarboxazid and Levalbuterol. Asthma [CA23] [14]
Pirbuterol DMI5678 Moderate Additive hypertensive effects by the combination of Isocarboxazid and Pirbuterol. Asthma [CA23] [15]
Ephedrine DMMV0KW Major Increased risk of hyperpyrexia by the combination of Isocarboxazid and Ephedrine. Asthma [CA23] [13]
Lisdexamfetamine DM6W8V5 Major Additive hypertensive effects by the combination of Isocarboxazid and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [13]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Isocarboxazid and Droxidopa. Autonomic nervous system disorder [8D87] [16]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Isocarboxazid and Olodaterol. Chronic obstructive pulmonary disease [CA22] [15]
Vilanterol DMF5EK1 Moderate Additive hypertensive effects by the combination of Isocarboxazid and Vilanterol. Chronic obstructive pulmonary disease [CA22] [14]
Indacaterol DMQJHR7 Moderate Additive hypertensive effects by the combination of Isocarboxazid and Indacaterol. Chronic obstructive pulmonary disease [CA22] [15]
Arformoterol DMYM974 Moderate Additive hypertensive effects by the combination of Isocarboxazid and Arformoterol. Chronic obstructive pulmonary disease [CA22] [15]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Isocarboxazid and Levomilnacipran. Chronic pain [MG30] [6]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Isocarboxazid and Cyclandelate. Dementia [6D80-6D8Z] [13]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Isocarboxazid and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [17]
LEVONORDEFRIN DMWDJ0H Moderate Additive hypertensive effects by the combination of Isocarboxazid and LEVONORDEFRIN. Discovery agent [N.A.] [18]
Tetrabenazine DMYWQ0O Major Additive hypertensive effects by the combination of Isocarboxazid and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [19]
Deutetrabenazine DMUPFLI Major Additive hypertensive effects by the combination of Isocarboxazid and Deutetrabenazine. Dystonic disorder [8A02] [19]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Isocarboxazid and Mephentermine. Essential hypertension [BA00] [13]
Solifenacin DMG592Q Minor Additive anticholinergic effects by the combination of Isocarboxazid and Solifenacin. Functional bladder disorder [GC50] [20]
Nesiritide DMFOIA8 Moderate Additive hypotensive effects by the combination of Isocarboxazid and Nesiritide. Heart failure [BD10-BD1Z] [13]
Tetrahydrozoline DMT57WC Moderate Decreased metabolism of Isocarboxazid caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme. Herpes simplex infection [1F00] [21]
Maraviroc DMTL94F Moderate Additive hypotensive effects by the combination of Isocarboxazid and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [13]
Aliskiren DM1BV7W Moderate Additive hypotensive effects by the combination of Isocarboxazid and Aliskiren. Hypertension [BA00-BA04] [13]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Isocarboxazid and Levamlodipine. Hypertension [BA00-BA04] [13]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Isocarboxazid and TAK-491. Hypertension [BA00-BA04] [13]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Isocarboxazid and Hydralazine. Hypertension [BA00-BA04] [13]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Isocarboxazid and Clevidipine butyrate. Hypertension [BA00-BA04] [13]
Belladonna DM2RBWK Minor Additive anticholinergic effects by the combination of Isocarboxazid and Belladonna. Infectious gastroenteritis/colitis [1A40] [20]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Isocarboxazid and Polyethylene glycol. Irritable bowel syndrome [DD91] [22]
Naphazoline DMJFZDL Moderate Decreased metabolism of Isocarboxazid caused by Naphazoline mediated inhibition of non-CYP450 enzyme. Itching [1F28-1G07] [21]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Isocarboxazid and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [23]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Isocarboxazid and Lasmiditan. Migraine [8A80] [6]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Isocarboxazid and Flibanserin. Mood disorder [6A60-6E23] [24]
Ozanimod DMT6AM2 Major Decreased metabolism of Isocarboxazid caused by Ozanimod mediated inhibition of non-CYP450 enzyme. Multiple sclerosis [8A40] [25]
Dextroamphetamine DMMIHVP Major Additive hypertensive effects by the combination of Isocarboxazid and Dextroamphetamine. Narcolepsy [7A20] [13]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Isocarboxazid and Phenindamine. Nasopharyngitis [CA00] [12]
Phendimetrazine DM6TS1N Major Increased risk of hyperpyrexia by the combination of Isocarboxazid and Phendimetrazine. Obesity [5B80-5B81] [13]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Isocarboxazid and Lorcaserin. Obesity [5B80-5B81] [26]
Propylhexedrine DMTBW2O Moderate Decreased metabolism of Isocarboxazid caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme. Obesity [5B80-5B81] [21]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Isocarboxazid and Polythiazide. Oedema [MG29] [13]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Isocarboxazid and Lofexidine. Opioid use disorder [6C43] [13]
Methamphetamine DMPM4SK Major Additive hypertensive effects by the combination of Isocarboxazid and Methamphetamine. Pain [MG30-MG3Z] [27]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Isocarboxazid and Silodosin. Prostate hyperplasia [GA90] [13]
Levomepromazine DMIKFEL Moderate Additive CNS depression effects by the combination of Isocarboxazid and Levomepromazine. Psychotic disorder [6A20-6A25] [13]
Selexipag DMAHSU0 Moderate Additive hypotensive effects by the combination of Isocarboxazid and Selexipag. Pulmonary hypertension [BB01] [13]
Avanafil DM75CXN Moderate Additive hypotensive effects by the combination of Isocarboxazid and Avanafil. Sexual dysfunction [HA00-HA01] [13]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [10]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin degludec. Type-1/2 diabete [5A10-5A11] [10]
Xylometazoline DMKV32D Moderate Decreased metabolism of Isocarboxazid caused by Xylometazoline mediated inhibition of non-CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [21]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Isocarboxazid and Acrivastine. Vasomotor/allergic rhinitis [CA08] [12]
⏷ Show the Full List of 54 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 27 E00381 83511 Colorant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Isocarboxazid 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7204).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 SCHWARTZ MA: The metabolism of isocarboxazid (marplan) in the rat. J Pharmacol Exp Ther. 1960 Oct;130:157-65.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
6 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
7 Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
8 Cerner Multum, Inc. "Australian Product Information.".
9 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
10 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
11 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
12 Canadian Pharmacists Association.
13 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
14 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
15 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
16 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
17 Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
18 Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
19 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
20 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
21 Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
22 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
23 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
24 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
25 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
26 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
27 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]